Notably, Atezolizumab outperformed docetaxel in patients with low or absent PD‐L1 expression, indicating the involvement of intricate mechanisms beyond PD‐L1 in the anti‐tumor efficacy of ICIs [26]. This evidence concerns the gene CD274 and neoplasm.